FDA grants priority review to New Drug Application for Tucatinib for Treatment of Locally Advanced or Metastatic HER2-Positive Breast Cancer

The application requests FDA approval of tucatinib in combination with trastuzumab and capecitabine, for patients who have received at least three prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.


Biospace Inc.